To include your compound in the COVID-19 Resource Center, submit it here.

Priority Review for Indivior's RBP-6000

Indivior plc (LSE:INDV) said FDA accepted and granted Priority Review to an NDA for RBP-6000 to treat

Read the full 170 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE